hvsa
Home
Courses
Course Objectives
Programs
CME Credits
Cases and Abstract Submissions
venue and accomodations
HVSA
Directors and Faculty
Videos
Register

 

New York City Conference

Back to 2014 Annual Meeting Abstracts


Production Of A New Generation Of Alpha-gal-free Bioprosthetic Tissues: Preliminary Results.
Filippo Naso1, Michele Spina2, Laura Iop1, Paola Aguiari1, Anabela C. Areias1, Catia M. Fidalgo1, Sugat R. Tuladhar1,
Gino Gerosa1.
1University Hospital of Padova, Padova, Italy, 2University of Padova, Padova, Italy.

OBJECTIVE: Xenogeneic grafts are currently employed for the healing of diseased tissues. Strangely enough their use is permitted even in absence of any assessment of the elimination of xenogeneic cell material, as the alpha-Gal epitopes. The currently treatment with glutaraldehyde (GLU) is unable to grant a complete immuno-tolerance, reducing but not eliminating the immunogenicity particularly for the alpha-Gal epitope (the major hindrance for the success of xenotransplantation). Recently, our group has extensively reported studies focused on the evaluation of biocompatibility properties of xenogeneic material including commercially heart valve bioprostheses. In order to meet the criteria for the creation of free-alpha-Gal bioprosthetic material we are developing a new procedure able to remove completely such undesiderable epitope from GLU fixed tissues. Here we have been reported the first encouraging results obtained by the treatment of commercially available equine pericardial patch (EPP).
METHODS: Commercially available EPP (XAG-400, Edwards Lifesciences) are processed for the quantitative evaluation of the alpha-Gal epitope by a patented ELISA test before and after treatment with an extract of vegetable origin (patent pending). Immunofluorescence analysis was performed in order to confirm data. Monoclonal antibody M86 was adopted as specific alpha-Gal detector.
RESULTS: The EPP exhibited 9.7 ± 4.9*10e10 alpha-Gal epitopes each 10 mg of wet weight tissue. Such antigen residues are exposed and reactive notwithstanding the GLU treatment to which the tissue is subjected by the manufacturer. Such amount resulted completely removed after the treatment with our extract as further confirmed by the immunofluorescence investigation.
CONCLUSIONS: First results showed that the removal of the alpha-Gal epitopes from GLU treated bioprosthetic tissue was possible without substantial modification in the manufacture process of biological devices. The elimination of the alpha-Gal residues will be able to ensure an improvement in the biocompatibility degree of the bioprosthetic tissue, avoiding the triggering of immunological/inflammatory chronic reaction and the onset of calcium enucleating site.


Back to 2014 Annual Meeting Abstracts

     

Home | Courses | Objectives | Program | CME Credit | Cases & Abstracts | Venu & Accomodations | HVSA | Committee & Faculty | Register | Privacy Policy